Christoph became CEO of INOFEA on August 15, 2025. With more than 25 years of international experience in business development, procurement, and R&D, he brings a strong track record of leadership and innovation. He has held senior positions at leading life science companies, including Novartis, Lonza, and Siegfried, in both Europe and the United States, and has also advised biotech start-ups on strategy and operations. Trained as an organic chemist, Christoph holds a master’s degree from Friedrich Schiller University in Jena and a Ph.D. in Biochemistry from the Technical University of Dresden, Germany.

Rita joined INOFEA in 2017 as Lab Head and progressively took on leadership responsibilities across R&D, Production and Quality Assurance, becoming Chief Technology Officer in 2023. She holds a bachelor’s and master’s degree in Biotechnology from the University of Palermo (Italy) and a Ph.D. in Biochemistry from ETH Zurich. During her postdoctoral research at the FHNW Institute of Chemistry and Bioanalytics, she developed the core technology that laid the foundation for INOFEA. Since joining the company, she has played a key role in advancing its technology platform and leading scientific and technical activities across R&D, production, and customer projects. Combining scientific expertise with technical and operational leadership, she bridges research and industrial application, helping translate innovative enzyme-based technologies into practical solutions for biotechnology and biomanufacturing in collaboration with international customers and partners.

Agnese holds a bachelor’s degree in Biological Sciences and a master’s degree in Molecular and Industrial Biotechnologies from the University of Naples Federico II, and a PhD in RNA Biology from the University of Zurich. Her research focused on protein-RNA interactions during an internship at the Centre for Protein Engineering of the University of Liège and on RNA-processing enzymes in ribosome biogenesis during her PhD. She joined INOFEA as R&D Group Leader for mRNA in vitro transcription (IVT), contributing to enzyme development, customer projects and research partnerships. As Business Development Leader, she combines scientific expertise and R&D management experience to develop customer relationships, strategic partnerships and new business opportunities. Working closely with R&D, she translates customer needs into tailored solutions in enzyme design, production, immobilization and shielding, while leading scientific marketing and communication.

Aaron earned a master’s degree in interdisciplinary sciences before completing his PhD in organic chemistry at ETH Zürich, where his research focused on protein engineering. As a discovery fellow at Novartis, he specialized in enzymatic peptide modification and bioconjugation. At INOFEA, he serves as Technology Platform Manager Bioconjugation, leading the development and advancement of INOFEA’s enzymatic bioconjugation platform, driving enzyme engineering and application development, and translating customer needs into innovative, technically viable solutions.

Tina earned a master’s degree in Biotechnology and Pharmaceutical R&D from the University of Rijeka, followed by a PhD in Biochemistry and Molecular Biology from Université Grenoble Alpes, working at the prestigious European Molecular Biology Laboratory (EMBL). During her PhD, she investigated the correlation between RNA structure and function. During her postdoc as a Marie Curie Postdoctoral Fellow, she explored RNA function in humans by applying CRISPR technology. Tina joined INOFEA as a Scientist for enzymatic mRNA in vitro transcription (IVT) and downstream purification, bringing her expertise in RNA biology to apply INOFEA’s technology to sustainable mRNA manufacturing. She now serves as Head of Operations (Laboratory, R&D & Production) within INOFEA’s R&D and small-scale production function.